Peel N F, Moore D J, Barrington N A, Bax D E, Eastell R
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, United Kingdom.
Ann Rheum Dis. 1995 Oct;54(10):801-6. doi: 10.1136/ard.54.10.801.
To determine the prevalence of vertebral fracture in postmenopausal women with steroid treated rheumatoid arthritis (RA), and whether the risk of vertebral fracture could be predicted from measurements of bone mineral density (BMD).
Vertebral deformities were defined from spine radiographs in 76 postmenopausal women with steroid treated RA (aged 50-79 years) and 347 age matched women from a population based group, using a morphometric technique. Lumbar spine (LS) BMD was measured by dual energy x ray absorptiometry.
The odds ratio for vertebral fracture in the women with RA was 6.2 (95% confidence interval 3.2 to 12.3). The decrease in LS-BMD was less than expected for the observed prevalence of vertebral fracture and, among the women with RA, LS-BMD was not lower in those with vertebral fractures.
We conclude that patients with steroid treated RA may have abnormal bone quality, and that LS-BMD cannot be used to predict the risk of vertebral fracture in these patients.
确定接受类固醇治疗的类风湿关节炎(RA)绝经后女性椎体骨折的患病率,以及能否通过骨密度(BMD)测量来预测椎体骨折风险。
采用形态测量技术,根据脊柱X光片对76例接受类固醇治疗的RA绝经后女性(年龄50 - 79岁)和347例来自人群对照组的年龄匹配女性进行椎体畸形判定。采用双能X线吸收法测量腰椎(LS)骨密度。
RA女性椎体骨折的比值比为6.2(95%置信区间3.2至12.3)。腰椎骨密度的降低低于观察到的椎体骨折患病率所预期的值,并且在患有RA的女性中,有椎体骨折的女性其腰椎骨密度并不更低。
我们得出结论,接受类固醇治疗的RA患者可能存在骨质异常,并且腰椎骨密度不能用于预测这些患者的椎体骨折风险。